Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  ponatinib hydrochloride
Find trials that include:  Any drugs shown
Results 1-7 of 7 for your search:
Start Over
Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients with Acute Lymphoblastic Leukemia
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 2011-0030, NCI-2011-02941, NCT01424982
Ponatinib Hydrochloride in Treating Patients with Stage IIIB-IV Non-Small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-103, NCI-2013-01802, NCT01813734
Ponatinib Hydrochloride in Treating Patients with Stage III-IV Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 13-2002, NCI-2013-01644, PAM004-1, PAM005-2, NCT01935336
Ponatinib Hydrochloride in Treating Patients with Advanced Biliary Cancer with FGFR2 Fusions
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1345, NCI-2014-02075, NCT02265341
Ponatinib Hydrochloride in Treating Patients with Refractory Metastatic Cancers and Genetic Alterations
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: OSU-14078, NCI-2014-01499, 14078, 2014C0143, NCT02272998
Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia (CML) to Characterize the Efficacy and Safety of a Range of Doses
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: AP24534-14-203, NCI-2015-01086, 2014-001617-12, NCT02467270
Ponatinib Hydrochloride in Treating Patients with Bevacizumab-Refractory Glioblastoma
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 15-163, NCI-2015-01746, AP24534-13-020, NCT02478164
Start Over